检验

订阅

MedSci主页 / 所有栏目 / 检验

Clinica Chimica Acta：白介素-32在冠心病患者的冠状动脉和血浆中增加？

2019-11-23 MedSci MedSci原创

白介素-32冠心病
关注

白细胞介素-32 (IL-32)是一种炎症环境中与心血管疾病高风险相关的细胞因子。本研究旨在探讨冠心病(CAD)患者的IL-32水平。

白细胞介素-32 (IL-32)是一种炎症环境中与心血管疾病高风险相关的细胞因子。本研究旨在探讨冠心病(CAD)患者的IL-32水平。

研究人员分析了正常和冠心病患者冠状动脉中IL-32的表达情况。等离子IL-32 IFN-γ和IL-17水平稳定心绞痛(SAP、n = 80)病人,不稳定心绞痛(UAP n = 96)患者中,急性心肌梗塞(AMI, n = 72)患者和患者出现胸痛与冠状动脉疾病无关(NCAD n = 72)测量。此外，还分析了血浆IL-32水平是否与冠心病的存在独立相关。

与正常冠状动脉相比，冠心病患者动脉粥样硬化斑块中高表达IL-32，巨噬细胞是IL-32的主要来源。与NCAD组相比，CAD组的IL-32，IFN-γ和IL-17水平升高，而SAP，UAP和AMI组则逐渐升高。 在CAD患者中，血浆IL-32水平与Gensini评分，IFN-γ水平和IL-17水平呈正相关。 线性回归的结果表明，IL-32与CAD的发生独立相关。

冠心病患者的冠状动脉和循环IL-32水平均升高，IL-32可能是无创诊断冠心病的标志。

原始出处：

Zicong Yang，Lei Shi，Interleukin-32 increases in coronary arteries and plasma from patients with coronary artery disease


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849795, encodeId=3cf11849e959e, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Oct 07 23:19:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372131, encodeId=c43513e213170, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Mon Nov 25 12:19:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447765, encodeId=87f5144e765d9, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Nov 25 12:19:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
    2020-10-07 windight

    #CTA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1849795, encodeId=3cf11849e959e, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Oct 07 23:19:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372131, encodeId=c43513e213170, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Mon Nov 25 12:19:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447765, encodeId=87f5144e765d9, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Nov 25 12:19:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
    2019-11-25 budeshao

    #白介素#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1849795, encodeId=3cf11849e959e, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Oct 07 23:19:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372131, encodeId=c43513e213170, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Mon Nov 25 12:19:00 CST 2019, time=2019-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447765, encodeId=87f5144e765d9, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Mon Nov 25 12:19:00 CST 2019, time=2019-11-25, status=1, ipAttribution=)]
    2019-11-25 柳叶一刀

    #冠心病患者#

    0